Coronavirus Vaccine Developed by German Research Group Fails in Early Trial
FILE PHOTO: An employee of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. Picture taken on March 12, 2020. REUTERS/Andreas Gebert/File Photo
Further testing has been suspended until the cause for the weak immunogenicity in the Hamburg trial involving 30 volunteers has been established, UKE said in a statement, adding that the vaccine was well tolerated.
- Reuters FRANKFURT
- Last Updated: January 08, 2021, 20:01 IST
- FOLLOW US ON:
A coronavirus vaccine developed by the German Centre for Infection Research (DZIF) and vaccine maker IDT Biologika did not prompt the hoped-for immune reaction in early-stage testing on humans, trial organisers at university hospital Hamburg-Eppendorf (UKE) said on Friday.
Further testing has been suspended until the cause for the weak immunogenicity in the Hamburg trial involving 30 volunteers has been established, UKE said in a statement, adding that the vaccine was well tolerated.
IDT said in November it was hoping to be able to apply for regulatory approval at the end of 2021.
